Pemlimogene merolisbac - Aduro Biotech/Jannsen Biotech

Drug Profile

Pemlimogene merolisbac - Aduro Biotech/Jannsen Biotech

Alternative Names: ADU 214; JNJ-64041757; Pemlimogene merolisbac

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aduro BioTech
  • Developer Aduro BioTech; Bristol-Myers Squibb; Janssen
  • Class Antineoplastics; Gene therapies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Ovarian-cancer(Combination therapy) in USA (Parenteral)
  • 18 Dec 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT03371381)
  • 17 Oct 2017 Interim efficacy and adverse events data from a phase I trial in Non-small cell lung cancer released by Aduro Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top